• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beyond The Numbers: 6 Analysts Discuss Agilon Health Stock

    7/9/24 11:00:57 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care
    Get the next $AGL alert in real time by email

    Analysts' ratings for Agilon Health (NYSE:AGL) over the last quarter vary from bullish to bearish, as provided by 6 analysts.

    Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 0 0 6 0 0
    Last 30D 0 0 1 0 0
    1M Ago 0 0 0 0 0
    2M Ago 0 0 2 0 0
    3M Ago 0 0 3 0 0

    Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $6.48, with a high estimate of $7.00 and a low estimate of $6.00. Highlighting a 5.4% decrease, the current average has fallen from the previous average price target of $6.85.

    price target chart

    Interpreting Analyst Ratings: A Closer Look

    The analysis of recent analyst actions sheds light on the perception of Agilon Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

    Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
    Elizabeth Anderson Evercore ISI Group Raises In-Line $7.00 $5.50
    Michael Halloran Baird Announces Neutral $6.00 -
    Jailendra Singh Truist Securities Raises Hold $6.50 $6.40
    Craig Jones Stifel Lowers Hold $7.00 $8.00
    Daniel Grosslight Citigroup Announces Neutral $6.00 -
    Jailendra Singh Truist Securities Lowers Hold $6.40 $7.50

    Key Insights:

    • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Agilon Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
    • Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Agilon Health compared to the broader market.
    • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Agilon Health's stock. This comparison reveals trends in analysts' expectations over time.

    Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agilon Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.

    Stay up to date on Agilon Health analyst ratings.

    Discovering Agilon Health: A Closer Look

    Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

    Agilon Health: A Financial Overview

    Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

    Revenue Growth: Agilon Health displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 52.17%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

    Net Margin: Agilon Health's net margin is impressive, surpassing industry averages. With a net margin of -0.38%, the company demonstrates strong profitability and effective cost management.

    Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.9%, the company showcases effective utilization of equity capital.

    Return on Assets (ROA): Agilon Health's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.3%, the company may face hurdles in achieving optimal financial performance.

    Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.07.

    What Are Analyst Ratings?

    Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

    In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGL

    DatePrice TargetRatingAnalyst
    8/20/2025$1.40Outperform → Mkt Perform
    Bernstein
    8/6/2025$1.00Buy → Neutral
    Citigroup
    4/25/2025$5.00Neutral → Buy
    Citigroup
    4/8/2025$8.50Mkt Perform → Outperform
    Bernstein
    1/10/2025$1.75 → $2.25Sell → Neutral
    Citigroup
    1/10/2025Hold
    Needham
    12/16/2024Neutral
    Macquarie
    12/11/2024$2.50Mkt Perform
    Bernstein
    More analyst ratings

    $AGL
    SEC Filings

    View All

    agilon health inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - agilon health, inc. (0001831097) (Filer)

    2/12/26 4:09:40 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    SEC Form PRE 14A filed by agilon health inc.

    PRE 14A - agilon health, inc. (0001831097) (Filer)

    2/6/26 7:07:31 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.

    SCHEDULE 13G/A - agilon health, inc. (0001831097) (Subject)

    1/30/26 1:27:24 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $AGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $AGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wulf John William bought $50,941 worth of shares (81,000 units at $0.63), increasing direct ownership by 28% to 365,857 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    1/30/26 7:30:58 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Financial Officer Schwaneke Jeffrey A. was granted 600,000 shares, increasing direct ownership by 56% to 1,675,122 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    1/13/26 4:44:56 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 406 shares, decreasing direct ownership by 0.35% to 114,752 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    8/19/25 5:39:24 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 868078. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the cal

    1/22/26 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health to Participate in the 8th Annual Evercore Healthcare Conference

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 3:00pm ET. Interested investors and other parties may listen to a simultaneous webcast of the presentation by visiting the "Events & Presentations" section of agilon health's investor relations website at https://investors.agilonhealth.com. Replays will be available for on-demand listening shortly after the completion of the presentation. About agilon health agilon health is the trusted partner empowering physici

    11/12/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Bernstein with a new price target

    Bernstein downgraded Agilon Health from Outperform to Mkt Perform and set a new price target of $1.40

    8/20/25 8:21:47 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health downgraded by Citigroup with a new price target

    Citigroup downgraded Agilon Health from Buy to Neutral and set a new price target of $1.00

    8/6/25 7:57:52 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Agilon Health upgraded by Citigroup with a new price target

    Citigroup upgraded Agilon Health from Neutral to Buy and set a new price target of $5.00

    4/25/25 8:23:09 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Director Wulf John William bought $50,941 worth of shares (81,000 units at $0.63), increasing direct ownership by 28% to 365,857 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    1/30/26 7:30:58 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: Chief Financial Officer Schwaneke Jeffrey A. bought $250,206 worth of shares (22,300 units at $11.22) and was granted 428,922 shares, increasing direct ownership by 61% to 1,130,552 units (SEC Form 4)

    4/A - agilon health, inc. (0001831097) (Issuer)

    4/3/25 7:40:25 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    CEO & President Sell Steven covered exercise/tax liability with 15,563 shares and bought 42,426 shares, increasing direct ownership by 8% to 355,310 units (SEC Form 4)

    4 - agilon health, inc. (0001831097) (Issuer)

    3/18/25 6:42:37 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Financials

    Live finance-specific insights

    View All

    agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the fourth quarter and full year 2025 after market close on Wednesday, February 25, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 868078. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the cal

    1/22/26 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Third Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the third quarter 2025 after market close on Tuesday, November 4, 2025 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 291396. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be availabl

    10/6/25 4:12:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Sets Date to Report Second Quarter 2025 Financial Results

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced that it will release its financial results for the second quarter 2025 after the market closes on Tuesday, August 5, 2025, and host a conference call at 4:30 PM Eastern Time the same day to discuss the results. The conference call can be accessed by dialing (833) 470-1428 for U.S. participants and +1 (404) 975-4839 for international participants and referencing participant code 938716. A simultaneous webcast can be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of t

    7/22/25 4:05:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Leadership Updates

    Live Leadership Updates

    View All

    agilon health Announces Leadership Transition

    Steven Sell steps down as President, Chief Executive Officer, and Board Director Ronald A. Williams, co-founder, Board Chairman, and healthcare industry veteran, appointed Executive Chairman Board establishes an Office of the Chairman and initiates search for permanent CEO Company reports second quarter 2025 earnings and withdraws full year 2025 guidance agilon health (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Steven Sell has stepped down as President, CEO, and a Director of the Board. Ronald A. Williams, the Company's co-founder and Board Chairman since 2017, has been appointed Executive Chairman. Williams

    8/4/25 4:10:00 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Appoints Karthik Rao, M.D., as Chief Medical Officer

    Dr. Rao to Continue to Lead Clinical Strategy and Drive Physician Network Performance Alongside agilon's Chief Clinical Officer Kevin Spencer, M.D. agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that after a comprehensive search Karthik Rao, M.D., who has served as agilon's interim chief medical officer (CMO) since February 2024, has been appointed to the permanent CMO role, effective immediately. He previously served as senior medical director and vice president, network performance, at the company. Prior to joining agilon in 2022, Dr. Rao held several roles in value-based care, including nearly a d

    7/10/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    agilon health Names Jeff Schwaneke New Chief Financial Officer

    agilon health, inc. (NYSE:AGL), the trusted partner empowering physicians to transform health care in our communities, announced today that Jeff Schwaneke, an experienced finance, operational and managed care executive and director on agilon's board, will join the Company as chief financial officer and executive vice president effective July 1, 2024. He will be a member of agilon's Executive Leadership team reporting to chief executive officer (CEO), Steve Sell. Schwaneke succeeds Timothy Bensley, who announced his retirement from agilon in early 2024. Bensley has agreed to stay on through a transition period. Schwaneke was most recently executive vice president, Health Care Enterprises,

    6/5/24 8:00:00 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    $AGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/13/24 12:49:26 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/8/24 10:52:39 AM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by agilon health inc.

    SC 13G/A - agilon health, inc. (0001831097) (Subject)

    11/6/24 4:47:14 PM ET
    $AGL
    Misc Health and Biotechnology Services
    Health Care